<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783639</url>
  </required_header>
  <id_info>
    <org_study_id>WIRION™ Pivotal Study (WISE)</org_study_id>
    <secondary_id>WIRION Study Europe (WISE)</secondary_id>
    <nct_id>NCT01783639</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting</brief_title>
  <acronym>WISE</acronym>
  <official_title>The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gardia Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gardia Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients
      undergoing carotid artery stenting to a performance goal based on an analysis of the results
      of previous US IDE carotid stenting with embolic protection studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient registry procedures include:

        -  Clinical Events Committee (CEC); responsibility for validating all reported primary
           safety outcomes

        -  Data Safety Monitoring Board (DSMB); to review and evaluate safety data including
           serious adverse events

        -  100% data monitoring; to compare data entered into the registry

        -  Source data verification; to assess the accuracy, completeness of registry data by
           comparing the data to external data sources (e.g., medical records, paper or electronic
           case report forms).

        -  Standard Operating Procedures; to address registry operations and analysis activities,
           such as patient recruitment, data collection, data management, data analysis and
           reporting for adverse events.

        -  Sample size assessment to specify the number of participants and follow up duration.

        -  Data Management Plan; to address situations where variables are reported as missing,
           unavailable, &quot;non-reported,&quot; uninterpretable, or considered missing because of data
           inconsistency or out-of-range results

        -  Statistical analysis plan; describing the analytical principles and statistical
           techniques to be employed in order to address the primary and secondary objectives, as
           specified in the study protocol or plan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.</measure>
    <time_frame>Within 30 Days of procedure</time_frame>
    <description>Each participant will be followed for 30 days of procedure during which the number of major cardiac and cerebral adverse events (Stroke, Death and Myocardial Infraction) will be counted to evaluate the device safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Rate of Device Success</measure>
    <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
    <description>Defined as a successful delivery, deployment and retrieval of WIRION™ without any complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Clinical Success</measure>
    <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
    <description>Defined as freedom from procedure related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Access Site Complications</measure>
    <time_frame>Within 30 Days of procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Events Occurring Within 30 Days Post Procedure,Including Strokes and Transient Ischemic Attacks</measure>
    <time_frame>Within 30 Days of procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
    <description>Successful completion of the protected stent procedure without angiographic complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
    <description>Defined as both device and angiographic success</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Carotid Artery Diseases</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid Artery Stent</intervention_name>
    <description>Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Anticipated patient life expectancy of at least 1 year

          -  Patient or authorized representative, signed a written Informed Consent form

          -  Patient is willing to comply with the protocol requirements

          -  Candidate for catheter-based therapy of a single stenosis located in the internal
             carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single
             FDA-approved stent with a carotid use indication

          -  Reference vessel diameter for intended filter location between 3.5mm and 6.0mm

          -  An adequate &quot;landing zone&quot; of at least 30mm

          -  Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50%
             for symptomatic patients OR ≥ 80% for asymptomatic patients

          -  At least one high surgical risk criteria, either anatomical or co-morbid risk factors,
             as listed below:

        Category I - Anatomical high risk factors

          -  Recurrent stenosis after endarterectomy

          -  Previous radical neck surgery or radiation therapy to the neck

          -  High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle

          -  Spinal immobility of the neck

          -  Tracheostomy or tracheal stoma

          -  Any laryngeal nerve palsy and bilateral carotid artery stenosis

        Category II - Co-morbid risk factors

          -  Contralateral carotid occlusion

          -  Unstable angina (Canadian Cardiovascular Society class III/IV)

          -  Congestive Heart Failure (New York Heart Association functional class III/IV) and/or
             known severe left ventricular dysfunction LVEF&lt;30%

          -  Requires coronary artery bypass surgery, cardiac valve surgery, major vascular
             surgery, or abdominal aortic aneurysm repair 31-60 days post carotid stent procedure

          -  Recent MI (&gt;72 hr and &lt;4 weeks)

          -  Severe pulmonary disease with FEV1 of &lt;30%

          -  CAD in ≥2 unrevascularized vessels with stenosis ≥70%

          -  Age ≥75 years

          -  Uncontrolled diabetes - Female patient with no child bearing potential or has negative
             pregnancy test within the previous 7 days and agrees to remain on birth control
             throughout the study

        Exclusion Criteria:

          -  Total occlusion or near-occlusion of the target vessel

          -  Severe lesion calcification

          -  Presence of an alternate source of emboli

          -  Presence of a filling defect, or angiographically visible thrombus, at target site

          -  A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion
             more severe than the target lesion

          -  Evolving, acute or recent stroke within the last 30 days

          -  Major stroke with a residual neurological deficit that would confound neurologic
             assessment

          -  Vertebrobasilar insufficiency symptoms only

          -  Major operation 30 days before or after the index procedure

          -  Ipsilateral intracranial stenosis that requires treatment

          -  Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in
             contralateral carotid within 30 days of the index procedure

          -  History of intracranial hemorrhage within 12 months

          -  Any condition that precludes proper angiographic assessment or prevents femoral
             arterial access

          -  Uncontrolled hypertension

          -  Contraindication to heparin and bivalirudin, aspirin, thienopyridines

          -  Known sensitivity to radiographic contrast media which cannot be controlled with
             pre-medication

          -  History or current indication of bleeding diathesis or coagulopathy

          -  Chronic renal insufficiency

          -  Carotid artery dissection or aortic arch anatomical anomalies

          -  Dementia or a neurological illness

          -  Patient is enrolled in another drug or device study protocol that has not reached its
             primary endpoint

          -  Severe pulmonary hypertension

          -  Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study
             participation inappropriate or confound neurologic assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig GmbH and Park-Krankenhaus Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Horst Sievert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardio Vascular Center Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Rohde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiologische Klinik, Klinikum Dortmund GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Schofer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz- und Gefäßzentrum Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Mudra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtisches Klinikum München GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Bosiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ St-Blasius, Dendermonde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaets Herzzentrum, Bad-Krozingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Cremonesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Villa Maria Cecilia, Contignola</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Reimers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mirano Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Schröder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ihre-Radiologen.de</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint Blasius Hospital, Department of Vascular Surgery</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets Herzzentrum</name>
      <address>
        <city>Bad-Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ihre-Radiologen.de</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund GmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum and Park-Krankenhaus</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München GmbH Klinikum Neuperlach</name>
      <address>
        <city>Munich</city>
        <zip>87137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villa Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <zip>48010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mirano Hospital</name>
      <address>
        <city>Mirano</city>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <results_first_submitted>June 8, 2015</results_first_submitted>
  <results_first_submitted_qc>June 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2015</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carotid</keyword>
  <keyword>Carotid artery stenting</keyword>
  <keyword>Stent</keyword>
  <keyword>Embolic protection</keyword>
  <keyword>Atherosclerotic Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WIRION</title>
          <description>Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent
Carotid Artery Stent: Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent
Carotid Artery Stent: Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.</title>
        <description>Each participant will be followed for 30 days of procedure during which the number of major cardiac and cerebral adverse events (Stroke, Death and Myocardial Infraction) will be counted to evaluate the device safety.</description>
        <time_frame>Within 30 Days of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent
Carotid Artery Stent: Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.</title>
          <description>Each participant will be followed for 30 days of procedure during which the number of major cardiac and cerebral adverse events (Stroke, Death and Myocardial Infraction) will be counted to evaluate the device safety.</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Device Success</title>
        <description>Defined as a successful delivery, deployment and retrieval of WIRION™ without any complications</description>
        <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Clinical Success</title>
        <description>Defined as freedom from procedure related serious adverse events</description>
        <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Access Site Complications</title>
        <time_frame>Within 30 Days of procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Events Occurring Within 30 Days Post Procedure,Including Strokes and Transient Ischemic Attacks</title>
        <time_frame>Within 30 Days of procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Success</title>
        <description>Successful completion of the protected stent procedure without angiographic complications</description>
        <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Defined as both device and angiographic success</description>
        <time_frame>Participants will be followed for the duration of the procedure, an expected average of 35 minutes</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>WIRION</title>
          <description>Device: WIRION™ Embolic Protection System
Interventions: Carotid Artery Stent
Carotid Artery Stent: Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low hemoglobin level</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia related to gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Admission at hospital with pain in segment L5/S1, protrusion of intervertebral discs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Incomplete occulomoric paresis because of hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Macular artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization due to aphasia and worsening of general health</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological/ Nervous system</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vardit Segal</name_or_title>
      <organization>Gardia Medical</organization>
      <phone>+972-4-6277166 ext 106</phone>
      <email>Vardit@Gardiamedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

